Chemistry:AZD-5423
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H21F4N3O3 |
| Molar mass | 487.455 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca[1] and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.[2][3][4][5][6]
It has completed a phase II clinical trial.[7]
See also
References
- ↑ "Selective Nonsteroidal Glucocorticoid Receptor Modulators for the Inhaled Treatment of Pulmonary Diseases". Journal of Medicinal Chemistry 60 (20): 8591–8605. October 2017. doi:10.1021/acs.jmedchem.7b01215. PMID 28937774.
- ↑ "AZD 5423 - AdisInsight". http://adisinsight.springer.com/drugs/800031497.
- ↑ "Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA". 2013. http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/.
- ↑ GB2010051905 Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
- ↑ SE2009050900 A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
- ↑ SE2009000264 Combination of (a) glucocorticoid receptor modulator and (b) a β2-agonist
- ↑ Clinical trial number NCT01555099 for "Multi-centre Study to Assess the Efficacy and Safety of AZD5423 in COPD Patients on a Background Therapy of Formoterol" at ClinicalTrials.gov
External links
 |  |
